OVITRELLE 250 micrograms/0.5 ml, solution for injection in a pre-filled syringe syringe, 0.5 ml
Active ingredients: CHORIOGONADOTROPINE ALFA
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OVITRELLE 250 microgrammes/0,5 ml solution injectable en seringue pré-remplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue préremplie en verre de 0,5 mL
- Marketing authorisation holder
- MERCK EUROPE (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Jan 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62616141CIP73622452CIP133400936224520Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHORIOGONADOTROPINE ALFAsolution | 250 microgrammes · 0,5 ml | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.